Navigation Links
Biological therapy with cediranib improves survival in women with recurrent ovarian cancer
Date:9/30/2013

king data," said Prof Ledermann. "Cediranib is the first oral VEGF tyrosine kinase inhibitor that has been shown to delay tumour progression and improve overall survival in recurrent ovarian cancer. It is simple to give for a prolonged period and in most patients it is well-tolerated." Adverse side-effects included high blood pressure, diarrhoea and fatigue.

A total of 456 patients whose ovarian cancer had recurred were enrolled in the trial in 63 centres from the UK, Canada, Australasia and Spain. They were randomised to receive platinum-based chemotherapy together with a placebo (the reference arm of the trial), or 20 mg a day of cediranib during chemotherapy followed by placebo for 18 months (concurrent arm of the trial), or 20 mg a day of cediranib during chemotherapy followed by cediranib as a maintenance treatment (maintenance arm).

"ICON6 has a three-arm design in which the effect of cediranib given with chemotherapy and continued as maintenance can be compared with standard chemotherapy. This is the first trial to have demonstrated a benefit of concurrent cediranib with chemotherapy, as well as demonstrating an additional benefit with maintenance cediranib," he said.

An increased survival time of nearly three months is significant in this group of patients. Prof Ledermann explained: "In previous ovarian cancer trials any improvement seen with each new treatment has been incremental. Survival has improved through sequential use of drugs. Most of the recent positive trials have shown an improvement in progression-free survival. Trials showing an improvement in overall survival are uncommon. Cediranib produces an incremental improvement in progression-free survival and an incremental improvement in overall survival. Although the average improvement in overall survival is 2.7 months, some patients will see a much more substantial benefit."

ECCO president, Professor Cornelis van de Velde, commented: "These are important resul
'/>"/>

Contact: Emma Mason
wordmason@mac.com
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Religious leaders can be key to biological diversity
2. Single-cell transfection tool enables added control for biological studies
3. Biological activity alters the ability of sea spray to seed clouds
4. Epigenetic changes shed light on biological mechanism of autism
5. PeerJ launches PeerJ PrePrints -- a preprint server for the biological and medical sciences
6. Declaring a truce with our microbiological frienemies
7. UMass Amherst researchers reveal mechanism of novel biological electron transfer
8. Biological wires carry electricity thanks to special amino acids
9. Wayne State University researchers techniques enable more, faster testing of biological liquids
10. Snooze button on biological clocks improves cell adaptability
11. Advance promises to expand biological control of crop pests
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... WINSTON-SALEM, N.C. , Jan. 16, 2015  A man-made ... working memory and other mental capabilities in adults with ... a pilot study led by researchers at Wake Forest ... 60 adults diagnosed with amnesic mild cognitive impairment (MCI) ...
(Date:1/22/2015)... 21, 2015  Analyst Report Issued by Small Cap IR. In ... that planet-wide, transactions at merchants on the leading payment cards ... of credit, debit, and prepaid cards reached 6.54 billion.  Eight ... fraudulent card usage in 2012, and credit and debit card ...
(Date:1/22/2015)...   EyeLock, Inc. , a market leader of iris-based identity ... to the new role of Senior Vice President of ... of mobile platforms and wearable solutions for EyeLock,s technologies. Gerber ... the semiconductor industry to his role at EyeLock, with expertise ...
Breaking Biology News(10 mins):Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 2Nasal Spray with Insulin Equivalent Shows Promise as Treatment for Adults with Mild Cognitive Impairment, Alzheimer's Dementia 3$4.80 Near Term Price Target with "Buy" given by CapRock Research for NXT-ID, Inc. (NASDAQ: NXTD) issued by Small Cap IR 2EyeLock Names Steve Gerber as Senior Vice President of Mobile and Wearables 2
... low levels of an asbestos-like mineral from Montana more ... for lung disease today, according to research from the ... a mineral with a flaky, fluffy-looking structure. Previous studies ... contained increased levels of an asbestos-like mineral fiber that ...
... is full of examples of creatures that try to look ... potential predators. But to avoid being eaten alive the larvae ... a way exchanging a dollar for a couple of dimes. ... dollar larvae created clones of themselves within 24 hours of ...
... Genome Sequencing Center (GSC) at Washington University in St. Louis, ... the corn genome. In the fall of 2005 ... (USDA) and the Department of Energy (DOE), awarded $32 million ... of the project led by the Washington University GSC is ...
Cached Biology News:Low exposure to asbestos-like mineral from Montana vermiculite may up lung disease risk 2Sand dollar larvae use cloning to 'make change,' confound predators 2Sand dollar larvae use cloning to 'make change,' confound predators 3All eyes and ears on the corn genome 2All eyes and ears on the corn genome 3
(Date:2/26/2015)... Feb. 26, 2015  NuGene International, Inc. ("NuGene") ... for skin and hair rejuvenation, has announced that ... of record for investor relations and strategic communications. ... distribution, sales and diversification strategies – and we ... prospective shareholders," stated Ali Kharazmi CEO of NuGene ...
(Date:2/26/2015)... IL (PRWEB) February 26, 2015 Already ... its gauging line by expanding its Length Gauge offerings ... ACANTO gauges. , Specifically, HEIDENHAIN’s pencil probe-style ... improved force specification. Two new 1Vpp, 12mm stroke ... lower force applications. One is a variant with a ...
(Date:2/26/2015)... Fla. , Feb. 26, 2015  Dyadic ... company whose patented and proprietary technologies are used ... proteins for the bioenergy, bio-based chemical, biopharmaceutical and ... report its financial results for year ending December ... 11, 2015 and will host a conference call ...
(Date:2/26/2015)... 2015  Epic Sciences announced today that President and ... the 35th Annual Cowen and Company Health Care Conference ... Room, 3rd Floor. The conference will be held at ... Epic is developing diagnostic tests of high clinical ... changes that occur during the course of cancer treatments. ...
Breaking Biology Technology:NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 2NuGene International, Inc. Selects Capital Market Relations for Strategic Investor Relations 3Accuracy and Versatile Gauging Go Hand in Hand at HEIDENHAIN 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 2Dyadic International To Announce Fourth Quarter 2014 Financial Results And Host Conference Call On Wednesday, March 11, 2015 3Epic Sciences to Present at 35th Annual Cowen and Company Health Care Conference 2
... Schering-Plough Corporation (NYSE: SGP ) will provide ... P. Koestler, Ph.D., executive vice president and president, Schering-Plough ... Conference in San Francisco on Monday, Jan. 12, at ... is expected to talk about the company,s R&D pipeline ...
... LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., ... that GSK has resubmitted the New Drug Application (NDA) ... approval of Solzira (TM) (gabapentin enacarbil) Extended ... Restless Legs Syndrome (RLS). The FDA had requested ...
... LONDON, January 9 UK medical technology company,BioCeramic ... Stephan Rietiker,has joined the company,s Board of Directors. ... in BioCeramic Therapeutics, targeted sectors,particularly as former President ... follows the recent appointment of another renowned,figure, Sir ...
Cached Biology Technology:GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 2GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome 3Dr Stephan Rietiker Joins BioCeramic Therapeutics 2
... immunological studies, vaccine development, and biosensor ... powerful Paraflo microfluidic on-chip synthesis platform. ... of our comprehensive Epitope Peptide Microarray ... Probe content is completely customer ...
... designed for quantitative assays using recombinant ... on the flexible and powerful Paraflo ... specified sequences can be synthesized on-chip ... with custom sequence design. These microarrays ...
... for the first time, you can identify ... more efficiently without interferences. The Agilent Multiple ... unwanted, multiple high-abundant proteins from human serum, ... just one device. With this revolutionary system, ...
... Microarrays designed for pathway studies, protein-protein ... (PTB) Studies built on the flexible ... platform. These microarrays are available as ... Microarray Service. Custom Probe ...
Biology Products: